Toxicity of drugs used for treatment of rhinitis: A reminder to the otorhinolaryngologist

American Journal of Rhinology

Volumn 14, Issue 2, 2000, Pages 77-82

  Balbani, Aracy P S ^a,c   Duarte, Jurandir G ^b   De Mello Jr , João F ^a   D'Antonio, Walmir E P ^a   Câmara, José ^a   Butugan, Ossamu ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Center for Toxicity Control   (Brazil)

^c NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEMIZOLE; AZELASTINE; BECLOMETASONE DIPROPIONATE; BROMPHENIRAMINE; CETIRIZINE; CHLORPHENIRAMINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLEMASTINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; DEXCHLORPHENIRAMINE; DIPHENHYDRAMINE; EBASTINE; EPHEDRINE; EPINASTINE; FEXOFENADINE; HYDROXYZINE; IPRATROPIUM BROMIDE; LEVOCABASTINE; NAPHAZOLINE; OXYMETAZOLINE; PHENYLEPHRINE; PHENYLPROPANOLAMINE; PROMETHAZINE; PSEUDOEPHEDRINE; TERFENADINE; UNINDEXED DRUG; XYLOMETAZOLINE;

ADOLESCENT; ADULT; ALLERGIC RHINITIS; ARTICLE; CHILD; DRUG MONITORING; DRUG OVERDOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAST CELL; RHINITIS; RISK BENEFIT ANALYSIS;

EID: 0034092850     PISSN: 10506586     EISSN: None     Source Type: Journal    
DOI: 10.2500/105065800781692903     Document Type: Article

References (17)

1. Meltzer EO. An overview of current pharmacotherapy in perennial rhinitis. J Allergy Clin Immunol 95:1097-1110, 1995.
2. Castelo A, Colombo AL, and Holbrook AM. Production and marketing of drugs in Brazil. J Clin Epidemiol 44(suppl II):21S-28S, 1991.
3. Simons FER. The eternal mangle: benefit ask, and cost of therapeutic agents. Ann Allergy Asthma Immunol 77:337-340, 1996.
4. Balbani APS, Nascimento EV, Sanchez TG, et al., Tratamento da rinite alérgica em crianças: prescrição leiga de medicamentos e intoxicações. Rev Pediatria (São Paulo) 17:249-256, 1997.
5. Vitezic D, Rozmanic V, Franulovic J, et al. Naphazoline nasal drops toxicity in children. Arh Hig Rada Toksikol 45:25-29, 1994.
6. Lake CR, Gallant S, Masson E, et al. Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports. Am J Med 89:195-208, 1990.
7. Backlin SA. Decongestant-induced hypertensive crisis. Canad Fam Physician 39:375-376, 1993.
8. Schiano TD, Somashekhar VB, Cassidy MJ, et al. Subfulminant liver failure and severe hepatotoxicity caused by loratadine use. Ann Intern Med 125:738-740, 1996.
9. Nishikawa M, Hikosaka, Yonemoto T, et al. A case of iatrogenic growth retardation induced by a corticosteroid-containing antiallergic drug. Horm Metab Res 27:376-378, 1995.
10. Bender B, and Milgrom H. Neuropsychiatric effects of medications for allergic diseases. J Allergy Clin Immunol 95:523-528, 1995.
11. Escobar JI, and Karno M. Chronic hallucinosis from nasal drops. JAMA 247:1859-1860, 1982.
12. Herridge CF, and A'Brook MF. Ephedrine psychosis. Br Med J 2:160, 1968.
13. Cetaruk EW, and Aaron CK. Hazards of nonprescription medications. Emerg Med Clin N Am 12:483-510, 1994.
14. King HC. Mast cell stabilizers. Otolaryngol Head Neck Surg 107:841-844, 1992.
15. Hofmann T, Wolf G, and Koidl B. In-vitro-Unter suchungen über die Wirkung vasokonstriktorischer Nasentropfen auf das Flimmerepithel der menschlichen Nasenschleimhaut. Laryngo-Rhino-Otol 74:564-567, 1995.
16. Scadding GK. Rhinitis medicamentosa (editorial). Clin Exp Allergy 25:391-394, 1995.
17. PR Vade Mécum - SEÇÃO I. São Paulo, Grupo Aché, 1996.